Document Detail

Behavioral counseling and varenicline treatment for smoking cessation.
MedLine Citation:
PMID:  20409497     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Smoking remains the primary preventable cause of death and illness in the U.S. Effective, convenient treatment programs are needed to reduce smoking prevalence.
PURPOSE: This study compared the effectiveness of three modalities of a behavioral smoking-cessation program in smokers using varenicline.
METHODS: Current treatment-seeking smokers (n=1202) were recruited from a large healthcare organization between October 2006 and October 2007. Eligible participants were randomized to one of three smoking-cessation interventions: web-based counseling (n=401); proactive telephone-based counseling (PTC; n=402); or combined PTC and web counseling (n=399). All participants received a standard 12-week FDA-approved course of varenicline. Self-report determined the primary outcomes (7-day point prevalent abstinence at 3- and 6-month follow-ups); the number of days varenicline was taken; and treatment-related symptoms. Behavioral measures determined utilization of both the web- and Phone-based counseling.
RESULTS: Intent-to-treat analyses revealed relatively high percentages of abstinence at 3 months (38.9%, 48.5%, 43.4%) and at 6 months (30.7%, 34.3%, 33.8%) for the web, PTC, and PTC-web groups, respectively. The PTC group had a significantly higher percentage of abstinence than the web group at 3 months (OR=1.48, 95% CI=1.12, 1.96), but no between-group differences in abstinence outcomes were seen at 6 months.
CONCLUSIONS: Phone counseling had greater treatment advantage for early cessation and appeared to increase medication adherence, but the absence of differences at 6 months suggests that any of the interventions hold promise when used in conjunction with varenicline.
Gary E Swan; Jennifer B McClure; Lisa M Jack; Susan M Zbikowski; Harold S Javitz; Sheryl L Catz; Mona Deprey; Julie Richards; Timothy A McAfee
Related Documents :
24373317 - Effect of holmium laser enucleation of prostate on overactive bladder symptoms and urod...
23039837 - Shunt survival after failed endoscopic treatment of hydrocephalus.
23883797 - Management of radiation-induced early nasal adhesion after radiotherapy for nasopharyng...
24930617 - Residual and recurrent gradients after septal myectomy for hypertrophic cardiomyopathy-...
24326967 - Surgically induced astigmatism following glaucoma surgery in egyptian patients.
23115677 - Treatment of hydrocephalus associated with neurosarcoidosis by multiple shunt placement.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  American journal of preventive medicine     Volume:  38     ISSN:  1873-2607     ISO Abbreviation:  Am J Prev Med     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-22     Completed Date:  2010-07-29     Revised Date:  2014-09-11    
Medline Journal Info:
Nlm Unique ID:  8704773     Medline TA:  Am J Prev Med     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  482-90     Citation Subset:  IM    
Copyright Information:
2010 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Benzazepines / therapeutic use*
Counseling / methods*
Middle Aged
Nicotinic Agonists / therapeutic use*
Outcome Assessment (Health Care)
Quinoxalines / therapeutic use*
Smoking Cessation / methods*
Grant Support
R01 CA071358/CA/NCI NIH HHS; R01 CA071358-09/CA/NCI NIH HHS
Reg. No./Substance:
0/Benzazepines; 0/Nicotinic Agonists; 0/Quinoxalines; W6HS99O8ZO/varenicline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Microbial quality of food available to populations of differing socioeconomic status.
Next Document:  Sports participation and problem alcohol use: a multi-wave national sample of adolescents.